MARKET

GKOS

GKOS

Glaukos Corp
NYSE
101.10
+2.15
+2.17%
After Hours: 101.10 0 0.00% 16:01 04/23 EDT
OPEN
99.49
PREV CLOSE
98.95
HIGH
101.24
LOW
98.31
VOLUME
351.10K
TURNOVER
0
52 WEEK HIGH
102.33
52 WEEK LOW
45.38
MARKET CAP
5.07B
P/E (TTM)
-36.3617
1D
5D
1M
3M
1Y
5Y
Why Glaukos Corporation (NYSE:GKOS) Could Be Worth Watching
Glaukos Corporation (NYSE:GKOS) saw a double-digit share price rise of over 10% in the past couple of months. The company is still trading at a fairly cheap price of $149.97 on the NYSE. Glaukos is expected to grow its profit by 59% over the next couple of years. The future growth of the company may not be fully reflected in the company's share price. GKOS is currently undervalued and could be an opportunity to buy the stock.
Simply Wall St · 1d ago
Weekly Report: what happened at GKOS last week (0415-0419)?
Weekly Report · 1d ago
Glaukos Announces the Release of its 2023 Sustainability Report
Glaukos Corporation has published its 2023 Sustainability Report. The report highlights the company’s continued commitment and progress on its key corporate sustainability initiatives. Glaukos is an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma.
Barchart · 04/16 15:05
Here's Why You Should Retain Glaukos (GKOS) Stock for Now
NASDAQ · 04/15 12:19
Weekly Report: what happened at GKOS last week (0408-0412)?
Weekly Report · 04/15 09:22
GLAUKOS CORP <GKOS.N>: TRUIST SECURITIES RAISES TARGET PRICE TO $120 FROM $110
Reuters · 04/15 08:25
Needham sees BSX, CNMD, RMD beating Street, despite medtech slow down
Needham sees BSX, CNMD, RMD and Surmodics beating Street, despite medtech slow down. Needham estimates medtech sales grew less than expected in Q1, but that Boston Scientific, CONMED and ResMed should still beat the Street. The investment firm says medtech market only grew by 5.3% in the first quarter of 2024.
Seeking Alpha · 04/14 21:56
Glaukos Price Target Raised to $100.00/Share From $85.00 by Mizuho
Dow Jones · 04/11 11:48
More
About GKOS
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. It develops novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders and retinal disease. Its product candidates include Micro-Invasive Glaucoma Surgery products that involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma and procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time. Its products include transdermal pharmaceuticals that are applied to the eyelid and designed to treat glaucoma, dry eye, presbyopia and other ocular surface diseases and disorders and micro-invasive, bio-erodible sustained release drug delivery implants to improve the vision of patients.

Webull offers Glaukos Corp stock information, including NYSE: GKOS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GKOS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GKOS stock methods without spending real money on the virtual paper trading platform.